Monday's AACR session kicked off with a plenary session on the future of cancer genomics. The Broad Institute's Levi Garraway discussed the big picture of cancer genomics, saying that although the prospect of curing solid tumors seems far away — and rather daunting — the key to understanding therapy resistance, and therefore to giving clinicians a chance to better treat their patients, is in using genomics approaches. Treatment resistance continues to be a problem, although the advent of combination therapies is starting to address this problem.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.